Market cap
₹46 Cr
Revenue (TTM)
₹104 Cr
P/E Ratio
--
P/B Ratio
1.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | 1.95 | 92.65 | -- |
| EBIT | -- | -- | 4.09 | 153.03 | -- |
| Net Profit | -- | -- | 7.03 | 134.09 | -- |
| EPS | -- | -- | -10.79 | 120.31 | -- |
| Book Value | -- | -- | 44.68 | 119.63 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-25 | Mar-24 | Mar-23 |
| EBIT-Margin
| 12.27 | -- | 14.59 | 14.29 | 7.93 |
| Net Margin
| 9.25 | -- | 11.11 | 10.64 | 5.98 |
| Return on equity
| 78.97 | -- | 53.78 | 104.71 | 78.42 |
| Return on Capital
| 103.66 | -- | 72.70 | 140.45 | 97.85 |
| Return on Assets
| 31.07 | -- | 28.11 | 40.00 | 25.08 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.01 |
Profitability
ROCE
72.70
Higher than Peers by 69.10
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
72.70
|
140.45
|
97.85
|
36.17
|
--
|
|
Peer Median
|
3.60
|
0.18
|
0.04
|
-3.34
|
--
|
ROE
53.78
Higher than Peers by 52.46
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
53.78
|
104.71
|
78.42
|
41.99
|
--
|
|
Peer Median
|
1.32
|
0.04
|
--
|
-0.62
|
--
|
ROA
28.11
Higher than Peers by 26.54
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
28.11
|
40.00
|
25.08
|
22.00
|
--
|
|
Peer Median
|
1.58
|
1.25
|
-0.37
|
-3.03
|
--
|
EBIT Margin
14.59
Higher than Peers by 25.03
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
14.59
|
14.29
|
7.93
|
6.44
|
--
|
|
Peer Median
|
-10.44
|
7.37
|
6.28
|
1.19
|
--
|
Net Margin
11.11
Higher than Peers by 7.09
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
11.11
|
10.64
|
5.98
|
6.22
|
--
|
|
Peer Median
|
4.02
|
7.38
|
1.96
|
6.70
|
--
|
Cash Profit Margin
11.43
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
11.43
|
10.81
|
6.08
|
6.45
|
--
|
|
Peer Median
|
--
|
0.00
|
0.00
|
0.00
|
--
|
Revenue Growth
1.95
Higher than Peers by 4.12
Year on year growth in net sales
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
1.95
|
119.54
|
219.45
|
--
|
--
|
|
Peer Median
|
-2.17
|
21.45
|
279.06
|
36.71
|
--
|
EBIT Growth
4.09
Higher than Peers by 65.23
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
4.09
|
295.96
|
293.07
|
--
|
--
|
|
Peer Median
|
-61.14
|
114.53
|
72.58
|
43.22
|
--
|
Net Profit Growth
7.03
Higher than Peers by 16.41
Year on year growth in profit after tax
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
7.03
|
290.12
|
207.23
|
--
|
--
|
|
Peer Median
|
-9.38
|
67.41
|
92.53
|
37.83
|
--
|
EPS Growth
-10.79
Higher than Peers by 52.15
Year on year growth in earnings per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
-10.79
|
290.12
|
207.23
|
--
|
--
|
|
Peer Median
|
-62.94
|
--
|
--
|
37.83
|
--
|
Book Value Growth
73.57
--
Year on year growth in book value per share
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
73.57
|
219.77
|
129.01
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
--
|
--
|
0.01
|
0.21
|
--
|
|
Peer Median
|
0.02
|
0.19
|
0.10
|
0.08
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
--
|
--
|
0.01
|
0.21
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.87
Lower than Peers by 0.18
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
1.87
|
1.50
|
1.26
|
1.24
|
--
|
|
Peer Median
|
2.06
|
1.80
|
2.14
|
2.27
|
--
|
Quick Ratio
1.38
Lower than Peers by 0.27
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
1.38
|
1.47
|
1.21
|
0.81
|
--
|
|
Peer Median
|
1.65
|
2.77
|
1.49
|
1.56
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
--
|
2,678.15
|
38.09
|
23.02
|
--
|
|
Peer Median
|
11.77
|
5.91
|
0.28
|
--
|
--
|
Operating Efficiency
Debtors to sales
19.20
Lower than Peers by 18.68
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
19.20
|
23.42
|
31.95
|
3.51
|
--
|
|
Peer Median
|
37.87
|
39.09
|
46.97
|
173.24
|
--
|
Asset Turnover
2.52
Higher than Peers by 2.37
Sales / Average Total Assets
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
2.52
|
3.76
|
4.19
|
3.53
|
--
|
|
Peer Median
|
0.14
|
0.41
|
0.26
|
0.14
|
--
|
Receivable days
76.95
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
76.95
|
69.31
|
60.32
|
12.81
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
17.33
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
17.33
|
2.04
|
5.97
|
21.31
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
-713.50
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
-713.50
|
--
|
--
|
-490.04
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
807.79
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
807.79
|
71.35
|
66.30
|
524.16
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
139.38
|
406.75
|
--
|
--
|
Price / Book Value
--
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
1.61
|
1.63
|
2.31
|
1.49
|
--
|
EV/EBITDA
0.36
Lower than Peers by 15.86
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
0.36
|
-0.39
|
-0.13
|
0.20
|
--
|
|
Peer Median
|
16.22
|
2.98
|
-3.29
|
-3.85
|
--
|
Market Cap
--
--
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
Mar-21
|
|---|---|---|---|---|---|
|
Studio LSD
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
85
|
83
|
59
|
55
|
--
|